0.00Open0.00Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover987.22%IV-89.75%PremiumAug 16, 2024Expiry Date0.47Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.1571Delta0.1816Gamma0.62Leverage Ratio-0.0068Theta-0.0004Rho-0.10Eff Leverage0.0003Vega
Spruce Biosciences Stock Discussion
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
Spruce Biosciences (Nasdaq: SPRB) and HMNC Brain Health announced a strategic collaboration to develop a treatment for Major Depressive Disorder (MDD) using Spruce's tildacerfont and HMNC's Cortibon Genetic Selection Tool. The Phase 2 study is set to begin in Q4 2024. Should the study be successful, Spruce has the option to acquire e...
$Iovance Biotherapeutics(IOVA.US)$ Phase 2
$Supernus Pharmaceuticals(SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$ Phase 2a
$MorphoSys(MOR.US)$ Phase 2
$Nuvation Bio(NUVB.US)$ Phase 2
$ALX Oncology(ALXO.US)$ Phase 2
$BioXcel Therapeutics(BTAI.US)$ Phase 2
$Purple Biotech(PPBT.US)$ Phase 2
$Arcus Biosciences(RCUS.US)$ Phase 2
$Medicenna Therapeutics(MDNAF.US)$ Phase 2b
$Affimed NV(AFMD.US)$ Phase 2
$Barinthus Biotherapeutics(BRNS.US)$ Phase 2b...
📊⚡️📊
No comment yet